News
Spark Therapeutics is riding a double shot of positive news about its gene therapy treatment for RPE65-mediated inherited retinal disorders that’s given its stock a…
Read More
With another failed trial of its glaucoma candidate trabodenoson in hand, Inotek Pharmaceuticals Corp. is pondering options that could include selling the company, but finding…
Read More
As Applied Genetic Technologies Corporation (AGTC) heads into the summer with encouraging results for two of its lead candidates using the adeno-associated virus-based gene technology…
Read More
Novartis Reports Positive Phase III Results for RTH258 Novartis reported that RTH258 (brolucizumab) 6 mg met the primary and key secondary endpoints of non-inferiority compared…
Read More
We see ophthalmology as one of the more innovative specialties in healthcare, but does that excitement translate to the public markets? In October, we launched…
Read More
When Novartis last week announced positive outcomes from two Phase III trials for new age-related macular degeneration (AMD) drug brolucizumab (RTH258), it seemed the other…
Read More
Now that the Implandata Ophthalmic Products has received approval to commercialize its implantable glaucoma-monitoring device in the European Union, it’s setting its sights on lining…
Read More
Now that Mynosys Cellular Devices has received FDA 510(k) clearance for its Zepto Capsulotomy System for cataract surgery, the company is planning its US launch…
Read More
Microinvasive glaucoma surgery (MIGS) pioneer Reay H. Brown, MD, has long advocated that surgery will be the best treatment option for glaucoma once safety and…
Read More
Alcon Launches Multifocal Toric IOL at ASCRS Alcon seized the platform of ASCRS 2017 to launch its AcrySof IQ ReSTOR +2.5 multifocal toric intraocular lens…
Read More
In October, we launched the OIS Index, a composite of ophthalmic growth stocks, to track the investment performance of our sector. Our goal is to…
Read More
With the recent report of successful top-line Phase III results of its fixed-dose glaucoma candidate Roclatan, Aerie Pharmaceuticals Inc. has seen its stock price soar…
Read More
SUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.
![OIS-ANTERIOR-NEW-DATE-750x420[4300]](https://ois.net/wp-content/uploads/2020/03/OIS-ANTERIOR-NEW-DATE-750x4204300.jpg "OIS-ANTERIOR-NEW-DATE-750x420[4300]")